Clinical Trial Update: A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

The study evaluating PT-523 in patients with advanced non-small cell lung cancer (Phase 1/2) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PT-523

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Non-Small-Cell Lung Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN